| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Odyssey Therapeutics, Inc.
13D
ODTX · 67613T104
|
7.1% |
5/15/2026
Event 5/8/2026
|
||||
| Dimension Management, L.P. | 7.1% | |||||
| Dimension Capital II, L.P. | 7.1% | |||||
| Dimension Capital II GP, LLC | 7.1% | |||||
| Dimension Management GP, LLC | 7.1% | |||||
| Adam Goulburn | 7.1% | |||||
| Zavain Dar | 7.1% | |||||
| Nan Li | 7.1% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.